PARP inhibitors

View All

ASCO GU 2023, Prostate & Urothelial Cancer Abstracts Highlights
A Quick Recap from ASCO GU 2023: Prostate and Urothelial Cancer Highlights

The ASCO Genitourinary (GU) Cancers Symposium, which ended on February 18, 2023, was a three-day scientific and educational meeting designed to provide attendees with in-depth, multidisciplinary analysis of the timely topics in the study, diagnosis, and treatment of GU malignancies. DelveInsight has compiled the sy...

Find More

PARP Inhibitors in Urothelial Carcinoma
PARP inhibitors in Urothelial carcinoma (UC): Hit or miss?

Chemotherapy, immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates are being used for treating Urothelial Carcinoma(UC) patients and now PARP inhibitors are being studied in UC in the neoadjuvant, first-line, maintenance therapy, and subsequent lines of the setting. It is worth n...

Find More

metastatic-colorectal-cancer-treatment-market
Novel and Emerging Metastatic Colorectal Cancer Treatment Drugs Anticipated to Change Market Dynamics

Colorectal cancer is a disease in which malignant (cancer) cells form in the tissues of the colon or the rectum. Colorectal Cancer is the third most lethal and fourth most commonly diagnosed cancer in the world. In 2020, nearly 2 million new cases were expected, with approximately 1 million deaths across the globe....

Find More

PARP Inhibitors making inroads into Ovarian Cancer

Ovarian Cancer is one of the commonly diagnosed cancer among women worldwide. It accounts for nearly 239,000 new cases and 152,000 deaths per year, globally. Treatment landscape of Ovarian Cancer has evolved over the years as the available chemotherapies were not that efficient, giving rise to targeted therapies as ...

Find More

The Snippet: Targeting metabolism in Renal Cell Carcinoma

Loss of VHL and elevated expression of HIF transcription factors leads to reprogramming of tumour cell metabolism, enabling renal cell carcinoma (RCC) cells to use carbons from glutamine-derived aspartate to drive pyrimidine biosynthesis. Now, researchers show that inhibition of glutamine availability decreases aspa...

Find More